ampelopsin has been researched along with Cancer of Nasopharynx in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, YT; Hsin, CH; Huang, CC; Lin, CW; Lu, YT; Su, CW; Wang, PH; Yang, SF | 1 |
| Ding, H; Huang, B; Li, CH; Lin, HG; Luo, GQ; Shi, JL; Zeng, JC; Zhao, Y | 1 |
2 other study(ies) available for ampelopsin and Cancer of Nasopharynx
| Article | Year |
|---|---|
Dihydromyricetin inhibits cancer cell migration and matrix metalloproteinases-2 expression in human nasopharyngeal carcinoma through extracellular signal-regulated kinase signaling pathway.
Topics: Cell Line, Tumor; Cell Movement; Extracellular Signal-Regulated MAP Kinases; Flavonols; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Signal Transduction | 2022 |
Dihydromyricetin promotes apoptosis, suppresses proliferation and tumor necrosis factor-α-mediated nuclear factor kappa-B activation in nasopharyngeal carcinoma CNE-2 cell.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Flavonols; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; NF-kappa B; Tumor Necrosis Factor-alpha | 2021 |